Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Maximum Tolerated Dose
  • Paclitaxel
  • Quinazolines

abstract

  • Gefitinib showed no added benefit in survival, TTP, or RR compared with standard chemotherapy alone. This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.07.215

PubMed ID

  • 14990633

Additional Document Info

start page

  • 785

end page

  • 94

volume

  • 22

number

  • 5